nd generation novel bi-specific CAR-T therapy targeting both CD19 and CD20 antigens
Indications: Relapsed/refractory B-cell non-Hodgkin s lymphoma (B-NHL)
C-CAR039 has been developed as a novel 2nd generation 4-1BB bi-specific CAR-T targeting both CD19 and CD20 antigens with an optimized bi-specific antigen binding domain. C-CAR039 can eradicate CD19/CD20 single or double positive tumor cells
in vitro and
invivo. The tissue cross reactivity and whole genome membrane proteome array studies further confirmed the specificity of C-CAR039.
C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies. The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies. These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response. Clinical trial in
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Cellular Biomedicine Group, Inc. Announces Completion of Merger
February 19, 2021 GMT
Cellular Biomedicine Group logo (PRNewsfoto/Cellular Biomedicine Group)
ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”) today announced the completion of the merger (the “Merger”) of the Company with CBMG Merger Sub Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Parent”), pursuant to the previously announced Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub.
Share this article
Share this article
ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ( CBMG or the Company ) today announced the completion of the merger (the Merger ) of the Company with CBMG Merger Sub Inc., a Delaware corporation ( Merger Sub ) and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ( Parent ), pursuant to the previously announced Agreement and Plan of Merger (the Merger Agreement ), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub.
Under the terms of the Merger Agreement, which was approved by the Company s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company s common stock, par value $0.001 per share (the Company Common Stock ), issued and outstanding immediately prior to the effective time of the Merger (the Effective Time ), other
/PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company s special meeting of stockholders held.
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger
News provided by
Share this article
Share this article
ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ( Company, CBMG, we or our ), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company s stockholders vote
FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the merger proposal ).